A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) (NCT06943872)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (7 items).
Location: Uci Health Laguna Hills — Laguna Hills, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Known active prolymphocytic leukemia or currently suspected Richter's transformation
- Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug
- Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD), requiring immunosuppressive drugs for treatment of GVHD, or have taken calcineurin inhibitors within 4 weeks prior to consent
- Known central nervous system involvement by CLL/SLL
- Severe or debilitating pulmonary disease
- Clinically significant cardiovascular disease NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (195 Sites)
- Uci Health Laguna Hills — Laguna Hills, California
- Chao Family Comprehensive Cancer Center — Orange, California
- Stanford Cancer Institute — Palo Alto, California
- Scripps Prebys Cancer Center — San Diego, California
- Rocky Mountain Cancer Centers (Williams) Usor — Aurora, Colorado
- Yale University Yale Cancer Center — New Haven, Connecticut
- Eastern Connecticut Hematology and Oncology — Norwich, Connecticut
- Cleveland Clinic Florida — Weston, Florida
- Northwestern University — Chicago, Illinois
- Illinois Cancer Specialists (Niles) Usor — Niles, Illinois
- University of Iowa Hospitals and Clinics — Iowa City, Iowa
- Mission Cancer and Blood — Waukee, Iowa
- University of Louisville, Brown Cancer Center — Louisville, Kentucky
- Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
- The University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
- Beth Israel Deaconess Medical Center (Bidmc) — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- The Cancer and Hematology Centers — Grand Rapids, Michigan
- Mayo Clinic Rochester — Rochester, Minnesota
- University of Nebraska Medical Center — Omaha, Nebraska
- Sidney Kimmel Comprehensive Cancer Center Washington Twp — Sewell, New Jersey
- Christus St Vincent Regional Cancer Center — Santa Fe, New Mexico
- Memorial Sloan Kettering Cancer Center Mskcc — New York, New York
- Optum Medical Care, Pc — Westbury, New York
- University of North Carolina At Chapel Hill — Chapel Hill, North Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.